// App-Quantinova.ai

: Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1

Researchers

Presenter

  • Cyrille Touzeau

Principal Investigators

  • Carolina Schinke

  • Monique C. Minnema

  • Jesus Berdeja

  • Albert Oriol

  • Niels WCJ van de Donk

  • Paula Rodriguez Otero

  • Elham Askari

  • Maria-Victoria Mateos

  • Luciano J. Costa

  • Jo Caers

  • Leo Rasche

  • Amrita Y. Krishnan

  • Deeksha Vishwamitra

  • Xuewen Ma

  • Xiang Qin

  • Katharine S. Gries

  • Kelly Kato

  • Michela Campagna

  • Tara Masterson

  • Brandi Hilder

  • Jaszianne Tolbert

  • Thomas Renaud

  • Jenna D. Goldberg

  • Chris Heuck

  • Philippe Moreau

  • Jesus San-Miguel

Medical Centers

  • Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR

  • University of Alabama at Birmingham Hospital, Vestavia, AL

  • University Hospital Hotel-Dieu, Nantes, France

  • Sarah Cannon Research Institute, Nashville, TN

  • Janssen Research & Development, Raritan, NJ

  • Mount Sinai School of Medicine, New York, NY

  • University of Liege, Liege, Belgium

  • Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain

  • Hospital Germans Trias i Pujol, Barcelona, Spain

  • University Hospital of Salamanca/IBSAL/CIC, Salamanca, Spain

  • Janssen Research & Development, Spring House, PA

  • University Medical Center, Utrecht, Netherlands

  • University of Navarra, Pamplona, Spain

  • Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands

  • University Hospital of Würzburg, Würzburg, Germany

  • City of Hope Comprehensive Cancer Center, Duarte, CA

  • Centre Hospitalier Universitaire de Nantes, Nantes, France

  • Janssen-Cilag, Madrid, Spain

Locations

  • United States

  • Netherlands

  • Spain

  • Germany

  • Belgium

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Solid malignancies

Biomarkers

  • Cluster of Differentiation 2AP

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved